Current Studies

We currently have many active studies and we continually have a number of trials in the developmental stage. The studies range from new ophthalmic devices to treat blepharospasm to retinal gene therapy for inherited genetic disease. At the Oxford Eye Hospital, we are incredibly fortunate to have a number of world class ophthalmologists who devote their time & expertise to clinical trials, across a variety of specialities.

If you are interested in learning more about the studies featured please click on the circle icons below or get in touch via our contact page.

DERBY: A Phase III, Multi-Center, Randomized, Double-Masked, Sham-Controlled Study to Compare the Efficacy and Safety of Intravitreal APL-2 Therapy with Sham Injections in Patients with Geographic Atrophy (GA) Secondary to Age-Related Macular Degeneration (AMD).

FOCUS: A study to test a new treatment for dry AMD.

Investigation of protein defects in retinal degenerations: This is a five year study assessing patients diagnosed with Retinal Degeneration.

MACTEL: A study to test a The Natural History Observation and Registry Study (NHOR).

PARTRIDGE: Investigating ocular (eye) and systemic (whole body) safety and tolerability using the active trial drug BI 765128 to treat Diabetic Macular Ischaemia (DMI).

PERCEIVE: This is a global non-interventional registry-based, post-authorization study (PASS) in paediatric and adult patients who have received Luxturna® sub-retinal injections in a real-world setting. 

PINNACLE: Deciphering AMD by deep phenotyping and machine learning

PressOp™ A new spectacle mounted device designed by clinicians to help individuals with Blepharospasm. 

SANDMAN: A randomised placebo-controlled trial to assess the effect of melatonin on circadian sleep-wake disturbances in ocular disease.

SCOPE: A natural history study in genetically defined patients with geographic atrophy secondary to age-related macular degeneration.

SeaSTAR: A new treatment for Stargardt disease (STGD).

SIRIUS: A study evaluating the effectiveness of new treatments for the causes of Retinitis Pigmentosa (RP).

UKIRDC: UK Inherited Retinal Disease Consortium.